Document Detail


Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications.
MedLine Citation:
PMID:  10198735     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since the introduction of percutaneous transluminal coronary angioplasty (PTCA), percutaneous intervention with balloon catheters, stents, and atherectomy devices has become a widely accepted practice. The persistent complication of non-Q-wave myocardial infarction (MI), as evidenced by increased cardiac enzyme levels after intervention, has aroused only moderate concern because its incidence was perceived to be small and not clinically relevant. With more systematic assessments of cardiac enzymes--specifically, creatine kinase (CK) and its MB isoform--evidence has begun to clarify both the incidence and the prognosis of periprocedural non-Q-wave MI: It appears to occur nearly three times more often than is clinically evident across all device types (8 to 9% of all interventions) and is directly and continuously associated with adverse outcomes, including late death. Although directional and rotational atherectomy improve angiographic outcome compared with PTCA, periprocedural infarction occurs at least twice as often with these newer technologies; the incidence associated with stent placement is comparable to and possibly higher than that of PTCA. Factors that may cause elevated CK-MB levels include distal embolization, side branch occlusion, thrombus, and coronary spasm. Analyses of the major trials of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors, a class of potent antiplatelet agents, show striking effectiveness of these drugs in reducing the incidence of "enzyme-only" or "silent" MI and in improving long-term clinical outcomes. The findings implicate platelet mediation in the occurrence of periprocedural infarction and suggest an important role for antiplatelet therapy, particularly GP IIb/IIIa receptor inhibition, in protecting patients undergoing percutaneous intervention.
Authors:
A A Adgey; T P Mathew; M T Harbinson
Related Documents :
8793585 - Thallium-201 myocardial perfusion imaging in patients before and after successful percu...
15080865 - A multi-centre randomised controlled trial of minimally invasive direct coronary bypass...
15139775 - Assessment of the safety and efficacy of the novel tetrapeptide itf-1697 on infarct siz...
8273975 - A comparison of patient charges associated with percutaneous transluminal coronary angi...
12757335 - Predictors of early outcome after coronary artery surgery in patients with severe left ...
12955425 - Pulsed doppler tissue imaging can help to identify patients with right ventricular infa...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical cardiology     Volume:  22     ISSN:  0160-9289     ISO Abbreviation:  Clin Cardiol     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-06-23     Completed Date:  1999-06-23     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  257-65     Citation Subset:  IM    
Affiliation:
Royal Victoria Hospital, Belfast, Northern Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects
Atherectomy / adverse effects
Biological Markers / analysis
Coronary Disease / therapy*
Creatine Kinase / metabolism*
Humans
Isoenzymes
Myocardial Infarction / enzymology*,  etiology*,  mortality,  pathology
Myocardial Revascularization / adverse effects*
Prognosis
Sensitivity and Specificity
Stents / adverse effects
Survival Rate
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Isoenzymes; EC 2.7.3.2/Creatine Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oral etoposide for patients with metastatic gastric adenocarcinoma.
Next Document:  Sudden death in dilated cardiomyopathy.